U.S. market Open. Closes in 5 hours 30 minutes

LLY | Eli Lilly and Company Stock Overview

(Stock Exchange: NYSE)
Day's Range 789.40 - 827.86
52 Week Range 711.40 - 972.53
Beta 0.45
Implied Volatility 48.01%
IV Rank 70.83%
Day's Volume 2,351,088
Average Volume 3,660,057
Shares Outstanding 947,989,000
Market Cap 782,953,594,990
Sector Healthcare
Industry Drug Manufacturers - General
IPO Date 1972-06-01
Valuation
Profitability
Growth
Health
P/E Ratio 70.71
Forward P/E Ratio 55.84
EPS 11.68
1YR Price Target 600.00
Dividend Yield 0.73%
Dividend Per Share 6.02
Dividend ExDate 2023-08-14
Dividend PayDate 2023-09-08
Employees 43,000
Country USA
Website LLY
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
LLY's peers: ABBV, ABT, AMGN, AZN, BMY, GILD, JNJ, PFE, MRK, NVS, OGN, SCLX
*Chart delayed
Analyzing fundamentals for LLY we got that it has average fundamentals where Valuation is considered to be significantly overvalued, Profitability is stunning wealthy, Growth is very good and Health is weak. For more detailed analysis please see LLY Fundamentals page.

Watching at LLY technicals we can see that long-term trend is bearish, while middle-term trend is bullish, but short-term trend is bearish. More technicals details can be found on LLY Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙